Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2026)

Insight Molecular Diagnostics has disclosed Gross Margin across 7 years of filings, most recently posting 46.88% for Q1 2026.

• Gross Margin for Q1 2026 came in at 46.88%, down 1510.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 51.31% (down 125.0% YoY), and the FY2025 annual result was 56.67%, up 1733.0% from the prior year.
• Gross Margin came in at 46.88% for Q1 2026 at Insight Molecular Diagnostics, up from 43.55% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 67.57% in Q2 2025 to a low of 401.49% in Q3 2022.
• The 5-year median for Gross Margin is 43.55% (2025), against an average of 10.59%.
• Across the five-year window, Gross Margin slumped 31348 bps in 2022 and soared 45930 bps in 2023, its largest moves.
• Insight Molecular Diagnostics' Gross Margin stood at 9.85% in 2022, then sank by 278 bps to 37.26% in 2023, then surged by 207 bps to 40.04% in 2024, then gained by 9 bps to 43.55% in 2025, then advanced by 8 bps to 46.88% in 2026.
• The last three Gross Margin figures came in at 46.88% (Q1 2026), 43.55% (Q4 2025), and 53.46% (Q3 2025), per Business Quant data.